Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on AbbVie (ABBV) to $211 from $215 and keeps a Buy rating on the shares as ...

AbbVie is another big pharmaceutical company made of many pieces moving in opposite directions. Its former lead drug is an anti-inflammatory injection called Humira. At recent prices, AbbVie stock ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

Humira is already facing competition from biosimilars in Europe, and will face a gang of cheaper near-copies in the US from early 2023 onwards when AbbVie’s patent protection expires.